France· FR:65261005
OYAVAS 25 mg/mL, solution à diluer pour perfusion
A medicinal product containing bévacizumab, registered in France by STADA ARZNEIMITTEL AG.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- BÉVACIZUMAB
- Manufacturer
- STADA ARZNEIMITTEL AG
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip1334009550813951 flacon(s) en verre de 4 ml
- cip1334009550814181 flacon(s) en verre de 16 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bévacizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsAbevmy 25 mg/ml concentraat voor oplossing voor infusieBiosimilar Collaborations Ireland Limited
- United KingdomAbevmy 100mg/4ml concentrate for solution for infusion vialsBiocon Biologics Ireland Ltd
- United StatesALYMSYSAmneal Pharmaceuticals LLC
- CzechiaABEVMYBiosimilar Collaborations Ireland Limited, Dublin
- BelgiumAbevmy 25 mg/mlBiosimilar Collaborations Ireland
- FinlandAbevmyBiosimilar Collaborations Ireland Limited
- SwitzerlandAbevmy
- SpainABEVMY 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONBiosimilar Collaborations Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Oyavas
- Iceland · Abevmy, Alymsys
- Liechtenstein · Abevmy, Alymsys
- Norway · Abevmy, Alymsys
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b5bacc2a-98ca-4cb1-9e2a-7bd2416db00f GET /v1/drugs/b5bacc2a-98ca-4cb1-9e2a-7bd2416db00f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "65261005",
"date_amm": "2021-03-26",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/20/1510",
"substance": "BÉVACIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about bévacizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.